Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS: Long-term Effects of Semaglutide on Diabetic Retinopathy in Type 2 Diabetes
NCT03811561Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2019
- Primary completion
- Nov 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in diabetic retinopathy (DR) comparing Semaglutide with Placebo (2 arms). Primary endpoint: Presence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression at 5 years. Started May 2019; status: active, not recruiting.
02
Drugs
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT03811561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03811561.